BeaconOne Healthcare Partners reposted this
The BeaconOne Healthcare Partners team hopes to see you at one of these upcoming conferences! #medicaldevices #medtech #marketaccess #reimbursement #healtheconomics
BeaconOne Healthcare Partners is a global life sciences strategy consulting firm founded by two consulting executives with decades of life sciences strategy consulting experience. We have supported medical technology innovators and investors across sectors (medical device, diagnostics, and biopharmaceuticals) through hundreds of assignments, providing guidance on their most complex business decisions.
External link for BeaconOne Healthcare Partners
Boston, US
BeaconOne Healthcare Partners reposted this
The BeaconOne Healthcare Partners team hopes to see you at one of these upcoming conferences! #medicaldevices #medtech #marketaccess #reimbursement #healtheconomics
The BeaconOne Healthcare Partners team hopes to see you at one of these upcoming conferences! #medicaldevices #medtech #marketaccess #reimbursement #healtheconomics
BeaconOne Healthcare Partners reposted this
In August 2024, the Centers for Medicare and Medicaid Services (CMS) established the Transitional Coverage for Emerging Technologies (TCET) pathway. TCET is intended to expedite national coverage for certain new technologies designated by the FDA as Breakthrough Devices. TCET leverages existing National Coverage Determination (NCD) and Coverage with Evidence Development (CED) processes to accelerate Medicare coverage for approved technologies. Medicare is the largest single healthcare purchaser in the United States and serves over 62 million beneficiaries. Access the link below to read more about the potential benefits of TCET and the US market challenges not changed by TCET. Subscribe to our newsletter for the latest BeaconOne news and insights! https://lnkd.in/e7e_QK8Y #MedTechEurope #MedTech #Medicaldevices #Reimbursement #MarketAccess #APACMTF
In August 2024, the Centers for Medicare and Medicaid Services (CMS) established the Transitional Coverage for Emerging Technologies (TCET) pathway. TCET is intended to expedite national coverage for certain new technologies designated by the FDA as Breakthrough Devices. TCET leverages existing National Coverage Determination (NCD) and Coverage with Evidence Development (CED) processes to accelerate Medicare coverage for approved technologies. Medicare is the largest single healthcare purchaser in the United States and serves over 62 million beneficiaries. Access the link below to read more about the potential benefits of TCET and the US market challenges not changed by TCET. Subscribe to our newsletter for the latest BeaconOne news and insights! https://lnkd.in/e7e_QK8Y #MedTechEurope #MedTech #Medicaldevices #Reimbursement #MarketAccess #APACMTF
BeaconOne Healthcare Partners reposted this
Today we are proud to announce a key milestone in the journey that began one year ago today with the formation of BeaconOne Healthcare Partners. Thanks to our fabulous team who have helped us get to this point and chart an exciting path for the future!
Today we are proud to announce a key milestone in the journey that began one year ago today with the formation of BeaconOne Healthcare Partners. Thanks to our fabulous team who have helped us get to this point and chart an exciting path for the future!
It was a privilege to collaborate on this important work with my former colleagues and the team from PreciseDx that demonstrates the potential cost savings achieved when a highly accurate and low-cost recurrence risk test is available at initial diagnosis and is widely accessible for all early-stage invasive breast cancer patients. #HealthEconomics #BreastCancer
Congratulations to BeaconOne Healthcare Partners’ Co-Founder and Managing Partner Thomas Goss and his coauthors on the recent publication of their economic impact study demonstrating the cost savings associated with the use of the PreciseBreast™ (also referred to as PDxBr) test compared to standard of care (SOC) risk assessment in a cohort of U.S. women with early-stage invasive breast cancer to aid in the treatment decision process (i.e. use of chemotherapy). The study compared the costs of treatment guided by the SOC risk assessment (i.e., 21 gene expression test and histopathology assessment) versus PreciseBreast™ in conjunction with SOC in a hypothetical U.S. commercial insurance plan with one million women, with an estimated 1,603 women in the plan diagnosed with early-stage invasive breast cancer. The study reports that use of PreciseBreast™ results in cost savings of $4M in year one compared to the current standard of care alone, with savings increasing to $12.5M over 6 years. See the press release here: https://lnkd.in/eRD4UnVe Link to the article here: https://lnkd.in/eXZDMxjj #PreciseDX #WomensHealth #BreastCancer
Congratulations to BeaconOne Healthcare Partners’ Co-Founder and Managing Partner Thomas Goss and his coauthors on the recent publication of their economic impact study demonstrating the cost savings associated with the use of the PreciseBreast™ (also referred to as PDxBr) test compared to standard of care (SOC) risk assessment in a cohort of U.S. women with early-stage invasive breast cancer to aid in the treatment decision process (i.e. use of chemotherapy). The study compared the costs of treatment guided by the SOC risk assessment (i.e., 21 gene expression test and histopathology assessment) versus PreciseBreast™ in conjunction with SOC in a hypothetical U.S. commercial insurance plan with one million women, with an estimated 1,603 women in the plan diagnosed with early-stage invasive breast cancer. The study reports that use of PreciseBreast™ results in cost savings of $4M in year one compared to the current standard of care alone, with savings increasing to $12.5M over 6 years. See the press release here: https://lnkd.in/eRD4UnVe Link to the article here: https://lnkd.in/eXZDMxjj #PreciseDX #WomensHealth #BreastCancer